Inside the research
West Pharmaceutical Services, Inc.
WST Research profile · latest available data
Price overview
$370.44
▼ -3.16 (-0.8%)
| 52w hi | $375.87 |
|---|---|
| 52w lo | $230.63 |
| Vol | 434.00K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.34
| Short | +0.27 |
|---|---|
| Medium | +0.45 |
| Long | +0.28 |
computed 2026-09-27
Key fundamentals
West Pharmaceutical Services, Inc.
Healthcare · Medical Instruments & Supplies
| Market cap | $26.07B |
|---|---|
| Enterprise value | $25.95B |
| Trailing P/E | 47.43x |
| Forward P/E | 37.11x |
| EV / EBITDA | 28.45x |
| P / S (ttm) | 7.84x |
| Profit margin | 17.0% |
| Return on equity | 19.1% |
| Revenue growth | +13.8% |
| Earnings growth | +18.1% |
| Debt / equity | 10.59 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.21 | |
| Sector | +0.08 | |
| Technical | +0.22 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Risk Metrics
| Beta vs SPX | 0.60 |
|---|---|
| Corr SPX | 0.21 |
| Annual vol | 47.0% |
| Annual ret | +21.3% |
| Sharpe | 0.45 |
| Max DD | -45.3% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $349.85 |
|---|---|
| High / Low | $400.00 / $310.00 |
| Median | $350.00 |
| Analysts | 13 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 10 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-27 | Barclays | → Equal-Weight |
| 2026-04-14 | Barclays | → Equal-Weight |
| 2026-02-13 | Barclays | → Equal-Weight |
| 2026-02-03 | Evercore ISI Group | → Outperform |
| 2025-12-02 | Morgan Stanley | → Equal-Weight |
| 2025-10-29 | TD Cowen | → Buy |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-23 | Earnings Release, Reg FD Disclosure… | read |
| 2026-07-14 | Material Agreement, Exhibits | read |
| 2026-06-01 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-05-11 | 1.05, Reg FD Disclosure… | read |
| 2026-05-05 | Shareholder Vote, Exhibits | read |
| 2026-04-23 | Earnings Release, Reg FD Disclosure… | read |
| 2026-03-09 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-12 | Earnings Release, Reg FD Disclosure… | read |
| 2025-10-23 | Earnings Release, Reg FD Disclosure… | read |
| 2025-09-11 | Officer / Director Change, Exhibits | read |
| 2025-07-24 | Earnings Release, Reg FD Disclosure… | read |
| 2025-07-21 | Officer / Director Change, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | McMahon Robert W. | SVP & Chief Financial Off | Option exercise | 794 | — |
| 2026-08-11 | McMahon Robert W. | SVP & Chief Financial Off | Withheld for tax | 346 | $121.40K |
| 2026-08-11 | McMahon Robert W. | SVP & Chief Financial Off | Option exercise | 6.35K | — |
| 2026-08-11 | McMahon Robert W. | SVP & Chief Financial Off | Withheld for tax | 2.76K | $971.07K |
| 2026-05-12 | Campbell Shane Alden | SVP, Proprietary Segment | Option exercise | 296 | — |
| 2026-05-12 | Campbell Shane Alden | SVP, Proprietary Segment | Withheld for tax | 84 | $26.32K |
| 2026-05-12 | Campbell Shane Alden | SVP, Proprietary Segment | Option exercise | 474 | — |
| 2026-05-12 | Campbell Shane Alden | SVP, Proprietary Segment | Withheld for tax | 135 | $42.11K |
| 2026-05-04 | Pucci Paolo | Grant | 791 | — | |
| 2026-05-04 | Michels Douglas A | Grant | 791 | — |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
Dividends
| Yield (TTM) | 0.18% |
|---|---|
| $ / share (TTM) | $0.66 |
| 5y CAGR | +5.5% |
Annual dividend per share
| 2021 | $0.69 |
|---|---|
| 2022 | $0.73 |
| 2023 | $0.77 |
| 2024 | $0.81 |
| 2025 | $0.85 |
| 2026 | $0.44 |
SEC Filings
The Long Run
FY 2010–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $2.89B | +7.5% | |
| Gross profit | $1.13B | +9.9% | |
| Operating income | $584.90M | +11.7% | |
| Net income | $493.70M | +33.8% | |
| Cash from ops | $776.50M | +13.1% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $372.01 | $372.14 | $368.45 | $370.44 | 434.00K |
| Sep 24 | $378.67 | $382.71 | $370.71 | $373.60 | 715.90K |
| Sep 23 | $370.93 | $376.06 | $368.20 | $375.87 | 876.90K |
| Sep 22 | $367.42 | $375.40 | $365.26 | $371.09 | 734.70K |
| Sep 21 | $363.78 | $366.12 | $361.05 | $361.78 | 506.80K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →